An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States.
VERDICT
The label
Markup
read at $9.69
Aveanna Healthcare Holdings Inc. holds its Markup at $9.69.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 180 days
Price
$9.69
Valuation
8.01 trailing · 12.48 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.89
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades at roughly a 31% discount to our $12.68 fair value, moderate competitive moat, 15.90% revenue growth.
Read at
$9.69
8.01 P/E · 12.48 fwd
Our fair value
$12.68
31% discount
Analyst target (avg)
$10.50
+8% to current
Target low $8.00Analyst target rangeTarget high $13.00
▲ current $9.69 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$9.69
you are here
Conservative
$11.14
+15%
Analyst avg
$10.50
+8%
Our fair value
$12.68
+31%
Analyst high
$13.00
+34%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
15.90%
Profit margin
10.37%
Debt to equity
623.92
Analyst consensus
Buy · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 93.7% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 12.2% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Home Care Growth Story Trips On Heavy Debt
Families want loved ones cared for at home rather than in expensive hospitals, and Aveanna sits in the middle of that shift with 16% revenue growth and a 10% profit margin. The numbers look tidy on paper, forward earnings at 12.5 times and a return on equity printed at 368%, yet the opportunity rating stays at avoid because the business fails the ethical screen on its debt ratio.
We pass for that single reason even though analysts lean buy and a modest margin of safety appears versus our fair value. The high return figure is likely inflated by leverage, not durable operating strength, and a moderate moat offers little protection if interest costs rise or reimbursement rates slip.
Debt levels create real fragility in a sector already exposed to regulatory and labour shocks. The ethical screen exists to flag exactly these cases before they become portfolio problems. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in AVAH's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
AVAH trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 45.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (10 analysts) rates it buy, with a mean price target of $10. Entered 2026-07-22 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-22Accumulation$9.69+45.1%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 45.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (10 analysts) rates it buy, with a mean price target of $10.
2026-07-18Accumulation$6.68+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (10 analysts) rates it buy, with a mean price target of $10.
2026-07-03Accumulation$6.68+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$6.68Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
